Regeneron
1Q Revenues: $3.2 billion (+7%)
1Q Earnings: $818 million (-16%)
Comments: First quarter Dupixent global sales (recorded by Sanofi) increased 37% to $2.5 billion in the quarter. EYLEA sales in the U.S. were $1.4 billion, down 6%. Libyayo sales in the U.S. were up 39% to $110 million. Praluent sales were $40 million in the quarter, up 18%. Evkeeza sales were up 88% to $15 million. Sanofi collaboration revenue was $798 million, up 26%. Bayer collaboration revenue was $357 million, down 7%. Roche collaboration revenue was $222 million, up 3%.